Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.


ESMO Colloquium: Controversies in endometrial cancer: Update on ESMO clinical practice guidelines (CPG) and future treatment direction

Tuesday, 15 September 2020, 13:00-14:30

This educational activity is provided by ESMO and funded by Eisai Europe Ltd.

  • Access new data on Endometrial Cancer
  • Learn about how treatment selection can rely on Molecular Biology features
  • Reposition the combined modality approach for RT/CT
  • Navigate within the various types of Endometrial cancers
  • Review the state of the Art and the updates in ESMO Guidelines and Consensus conference

ESMO Colloquium: Precision Medicine Implementation in the Clinic:  RET as a potential target in cancer treatment

Tuesday, 22 September 2020, 13:00-14:30

This educational activity is provided by ESMO and supported by Lilly.

  • Understand the role of RET and its molecular alteration in cancer biology
  • Review the present results of RET targeting in Thyroid and Non-Small-Cell Lung carcinomas
  • Access the latest ESMO recommendations on RET in Breast cancer
  • Consider RET as a possible target for an agnostic treatment approach

ESMO Colloquium: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Wednesday, 23 September 2020, 13:00-14:30

This educational activity is provided by ESMO and supported by Lilly.

  • Review the recent outcomes of EGFR mutant metastatic NSCLC treated with 3rd generation EGFR TKI
  • Decide whether or not single agent EGFR TKI is still standard of care
  • Access recent combination data of EGFR TKI with either chemotherapy or anti-angiogenic or even Immune-checkpoint inhibitors

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.